Clinical studies have also shown that the three isoforms are overexpressed in ovarian cancers with the predominant expression patterns either dual or triple co-expression [11-13] suggesting that TGF-β1, TGF-β2 and TGF-β3 may function similarly. This evidence concerns the gene TGFB2 and ovarian carcinoma.